Psychiatr Prax 2004; 31(7): 330-338
DOI: 10.1055/s-2004-828378
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Vaskuläre Demenzen - Diagnostik, Prävention und Therapie

Vascular Dementia - Diagnosis, Prevention and TreatmentHenrike  Wolf1 , Hermann-Josef  Gertz2
  • 1Karolinska Institutet, Neurotec, Abteilung für Klinische Geriatrie, Huddinge, Schweden
  • 2Klinik und Poliklinik für Psychiatrie der Universität Leipzig
Die Arbeit wurde unterstützt durch das Interdisziplinäre Zentrum für klinische Forschung (Leipzig, IZKF C8). H. W. erhielt Stipendien der Gun och Bertil Stohnes Stiftelse und Demensstiftelse (Schweden)
Further Information

Publication History

Publication Date:
05 October 2004 (online)

Zusammenfassung

Anliegen: Die vorliegende Arbeit gibt einen Überblick über aktuelle Trends auf dem Gebiet der vaskulären Demenzen (VaD). Methode: Ausgehend von Definition und Pathophysiologie der VaD werden diagnostische Ansätze und aktuelle Ergebnisse aus Studien zur Prävention und Therapie der VaD dargestellt. Ergebnisse: Erste randomisierte Interventionsstudien belegen die Wirksamkeit präventiver Strategien bei VaD. Für die medikamentöse Therapie der manifesten VaD hat bisher keine Substanz eine Zulassung erhalten. Schlussfolgerungen: Die langfristige Kontrolle vaskulärer Risikofaktoren vor dem Auftreten einer Demenz ist die wichtigste Maßnahme zur Reduzierung der Inzidenz vaskulärer Demenzen.

Abstract

Objective: In this article, current trends in diagnosis, prevention and therapy of vascular dementias (VaD) are summarized. Methods: Based on the conceptual background and pathophysiology of VaD, current diagnostic approaches and results from recent large-scale randomised preventative and therapeutic studies are reviewed. Results: Epidemiological cohort studies and first intervention trials with anithypertensive drugs demonstrated the usefulness of antihypertensive drugs in the prevention of dementia. For the treatment of manifest VaD, no pharmaceutical substance has been approved to date, despite positive results in controlled studies with acetylcholinestere inhibitors. Conclusions: Long-term control of vascular risk factors before dementia has occurred appears to be the most important strategy to reduce the incidence of VaD.

Literatur

  • 1 Fratiglioni L, Launer L J, Andersen K, Breteler M M, Copeland J R, Dartigues J F, Lobo A, Martinez-Lage J, Soininen H, Hofman A. Incidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group.  Neurology. 2000;  54 S10-S15
  • 2 Statistisches Bundesamt .Gesundheitsbericht für Deutschland. Stuttgart; Metzler-Poeschel 1998
  • 3 Pohjasvaara T, Erkinjuntti T, Vataja R, Kaste M. Comparison of stroke features and disability in daily life in patients with ischemic stroke aged 55 to 70 and 71 to 85 years.  Stroke. 1997;  28 729-735
  • 4 Vermeer S E, Prins N D, Heijer T den, Hofman A, Koudstaal P J, Breteler M M. Silent brain infarcts and the risk of dementia and cognitive decline.  N Engl J Med. 2003;  348 1215-1222
  • 5 Snowdon D A, Greiner L H, Mortimer J A, Riley K P, Greiner P A, Markesbery W R. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study.  JAMA. 1997;  277 813-817
  • 6 Esiri M M, Nagy Z, Smith M Z, Barnetson L, Smith A D. Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer's disease.  Lancet. 1999;  354 919-920
  • 7 Wolf H, Ecke G M, Bettin S, Dietrich J, Gertz H J. Do white matter changes contribute to the subsequent development of dementia in patients with mild cognitive impairment? A longitudinal study.  Int J Geriatr Psychiatry. 2000;  15 803-812
  • 8 Torre J C de la. Alzheimer disease as a vascular disorder: nosological evidence.  Stroke. 2002;  33 1152-1162
  • 9 Alzheimer A. Die Seelenstörungen auf arteriosklerotischer Grundlage.  Allg Z Psychiat. 1902;  59 695-711
  • 10 Pohjasvaara T, Mantyla R, Ylikoski R, Kaste M, Erkinjuntti T. Clinical features of MRI-defined subcortical vascular disease.  Alzheimer Dis Assoc Disord. 2003;  17 236-242
  • 11 Nissl F. Zur Kasuisitik der arteriosklerotischen Demenz (Ein Fall von sogenannter „Encephalitis subcorticalis”).  Z ges Neurol Psychiat. 1920;  19 438-443
  • 12 Roman G C, Erkinjuntti T, Wallin A, Pantoni L, Chui H C. Subcortical ischaemic vascular dementia.  Lancet Neurol. 2002;  1 426-436
  • 13 Roman G C, Tatemichi T K, Erkinjuntti T, Cummings J L, Masdeu J C, Garcia J H, Amaducci L, Orgogozo J M, Brun A, Hofman A. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop.  Neurology. 1993;  43 250-260
  • 14 American Psychiatric Association .DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, ed 4th. Washington D. C.; American Psychiatric Press 1994
  • 15 Chui H C, Victoroff J I, Margolin D, Jagust W, Shankle R, Katzman R. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers.  Neurology. 1992;  42 473-480
  • 16 World Health Organisation .International Classification of Diseases, ed. 10. Geneva; 1990
  • 17 Binswanger O. Die Abgrenzung der allgemeinen progressiven Paralyse (Referat erstattet auf der Jahresversammlung des Vereins deutscher Irrenärzte zu Dresden am 20. September 1804).  Berl klin Wschr. 1894;  31 1103-1105, 1137 - 1139, 1180 - 1189
  • 18 Erkinjuntti T, Inzitari D, Pantoni L, Wallin A, Scheltens P, Rockwood K, Roman G C, Chui H, Desmond D W. Research criteria for subcortical vascular dementia in clinical trials.  J Neural Transm Suppl. 2000;  59 23-30
  • 19 Pasquier F. Early diagnosis of dementia: neuropsychology.  J Neurol. 1999;  246 6-15
  • 20 O'Brien J T, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, Bowler J V, Ballard C, DeCarli C, Gorelick P B, Rockwood K, Burns A, Gauthier S, DeKosky S T. Vascular cognitive impairment.  Lancet Neurol. 2003;  2 89-98
  • 21 Rosen W G, Terry R D, Fuld P A, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias.  Ann Neurol. 1980;  7 486-488
  • 22 Wolf H, Hensel A, Kruggel F, Riedel-Heller S G, Arendt T, Wahlund L O, Gertz H J. Structural correlates of mild cognitive impairment.  Neurobiol Aging. 2004;  25 913-924
  • 23 Behrens T E, Johansen-Berg H, Woolrich M W, Smith S M, Wheeler-Kingshott C A, Boulby P A, Barker G J, Sillery E L, Sheehan K, Ciccarelli O, Thompson A J, Brady J M, Matthews P M. Non-invasive mapping of connections between human thalamus and cortex using diffusion imaging.  Nat Neurosci. 2003;  6 750-757
  • 24 Klunk W E, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt D P, Bergstrom M, Savitcheva I, Huang G F, Estrada S, Ausen B, Debnath M L, Barletta J, Price J C, Sandell J, Lopresti B J, Wall A, Koivisto P, Antoni G, Mathis C A, Langstrom B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.  Ann Neurol. 2004;  55 306-319
  • 25 Weih M, Muller-Nordhorn J, Amberger N, Masuhr F, Lurtzing F, Dreier J P, Hetzel A. Risk in ischemic stroke-review of evidence in primary prevention.  Nervenarzt. 2004;  75 324-335
  • 26 Leys D, Kwiecinski H, Bogousslavsky J, Bath P, Brainin M, Diener H C, Kaste M, Sivenius J, Hennerici M G, Hacke W. Prevention. European Stroke Initiative.  Cerebrovasc Dis. 2004;  17, Suppl 2 15-29
  • 27 Moroney J T, Bagiella E, Desmond D W, Paik M C, Stern Y, Tatemichi T K. Risk factors for incident dementia after stroke. Role of hypoxic and ischemic disorders.  Stroke. 1996;  27 1283-1289
  • 28 Forette F, Seux M L, Staessen J A, Thijs L, Babarskiene M R, Babeanu S, Bossini A, Fagard R, Gil-Extremera B, Laks T, Kobalava Z, Sarti C, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Birkenhager W H. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study.  Arch Intern Med. 2002;  162 2046-2052
  • 29 Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, Chalmers J. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease.  Arch Intern Med. 2003;  163 1069-1075
  • 30 Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial.  J Hypertens. 2003;  21 875-886
  • 31 Castelli W P, Anderson K, Wilson P W, Levy D. Lipids and risk of coronary heart disease. The Framingham Study.  Ann Epidemiol. 1992;  2 23-28
  • 32 Stamler J, Vaccaro O, Neaton J D, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial.  Diabetes Care. 1993;  16 434-444
  • 33 Piechowski-Jozwiak B, Bogousslavsky J. Cholesterol as a risk factor for stroke: the fugitive?.  Stroke. 2004;  35 1523-1524
  • 34 Amarenco P, Lavallee P, Touboul P J. Stroke prevention, blood cholesterol, and statins.  Lancet Neurol. 2004;  3 271-278
  • 35 Notkola I L, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, Kivinen P, Tuomilehto J, Nissinen A. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease.  Neuroepidemiology. 1998;  17 14-20
  • 36 Kivipelto M, Helkala E L, Laakso M P, Hanninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissien A. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study.  BMJ. 2001;  322 1447-1451
  • 37 Launer L J, White L R, Petrovitch H, Ross G W, Curb J D. Cholesterol and neuropathologic markers of AD: a population-based autopsy study.  Neurology. 2001;  57 1447-1452
  • 38 Exel E van, Craen A JM de, Gussekloo J, Houx P, Bootsma-Wiel A van der, Macfarlane P W, Blauw G J, Westendorp R GJ. Association between high-density lipoprotein and cognitive impairment in the oldest old.  Ann Neurol. 2002;  51 716-721
  • 39 Wolozin B, Kellman W, Ruosseau P, Celesia G G, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.  Arch Neurol. 2000;  57 1439-1443
  • 40 Jick H, Zornberg G L, Jick S S, Seshadri S, Drachman D A. Statins and the risk of dementia.  Lancet. 2000;  356 1627-1631
  • 41 Yaffe K, Barrett-Connor E, Lin F, Grady D. Serum lipoprotein levels, statin use, and cognitive function in older women.  Arch Neurol. 2002;  59 378-384
  • 42 Collins R, Armitage J, Parish S, Sleight P, Peto R. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions.  Lancet. 2004;  363 757-767
  • 43 Shepherd J, Blauw G J, Murphy M B, Bollen E L, Buckley B M, Cobbe S M, Ford I, Gaw A, Hyland M, Jukema J W, Kamper A M, Macfarlane P W, Meinders A E, Norrie J, Packard C J, Perry I J, Stott D J, Sweeney B J, Twomey C, Westendorp R G. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.  Lancet. 2002;  360 1623-1630
  • 44 Gorelick P B. Neuroprotection in acute ischaemic stroke: a tale of for whom the bell tolls?.  Lancet. 2000;  355 1925-1926
  • 45 Nhan H, Barquist K, Bell K, Esselman P, Odderson I R, Cramer S C. Brain function early after stroke in relation to subsequent recovery.  J Cereb Blood Flow Metab. 2004;  24 756-763
  • 46 Gertz H J, Wolf H, Arendt T. Vaskuläre Demenz (Vascular Dementia).  Nervenarzt. 2002;  73 393-404
  • 47 Lopez-Arrieta J M, Birks J. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev 2002, CD000147
  • 48 Wilcock G, Mobius H J, Stoffler A. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500).  Int Clin Psychopharmacol. 2002;  17 297-305
  • 49 Orgogozo J M, Rigaud A S, Stoffler A, Mobius H J, Forette F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).  Stroke. 2002;  33 1834-1839
  • 50 Wallin A, Alafuzoff I, Carlsson A, Eckernas S A, Gottfries C G, Karlsson I, Svennerholm L, Winblad B. Neurotransmitter deficits in a non-multi-infarct category of vascular dementia.  Acta Neurol Scand. 1989;  79 397-406
  • 51 Black S, Roman G C, Geldmacher D S, Salloway S, Hecker J, Burns A, Perdomo C, Kumar D, Pratt R. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial.  Stroke. 2003;  34 2323-2330
  • 52 Wilkinson D, Doody R, Helme R, Taubman K, Mintzer J, Kertesz A, Pratt R D. Donepezil in vascular dementia: a randomized, placebo-controlled study.  Neurology. 2003;  61 479-486
  • 53 Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju C V. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial.  Lancet. 2002;  359 1283-1290
  • 54 Moretti R, Torre P, Antonello R M, Cazzato G, Bava A. Rivastigmine in subcortical vascular dementia: a randomized, controlled, open 12-month study in 208 patients.  Am J Alzheimers Dis Other Demen. 2003;  18 265-272
  • 55 Bates J, Boote J, Beverley C. Psychosocial interventions for people with a milder dementing illness: a systematic review.  J Adv Nurs. 2004;  45 644-658
  • 56 Kruglov L S. The early stage of vascular dementia: significance of a complete therapeutic program.  Int J Geriatr Psychiatry. 2003;  18 402-406
  • 57 Spector A, Thorgrimsen L, Woods B, Royan L, Davies S, Butterworth M, Orrell M. Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia: randomised controlled trial.  Br J Psychiatry. 2003;  183 248-254
  • 58 Koch K. MONICA-Projekt. Eine Todesursache ändert ihren Charakter.  Deutsches Ärzteblatt. 2000;  97 A583-A584
  • 59 Scherpinski U, Bickel H, Gnahn H, Forstl H, Conrad B, Sander D. Intervention project on cerebrovascular diseases and dementia in the Ebersberg district (INVADE): rationale and design.  Nervenarzt. 2002;  73 1199-1204

Dr. Henrike Wolf

Karolinska Institutet · Neurotec

Karolinska Sjukhus Huddinge, B 84

14155 Huddinge · Schweden

Email: henrike.wolf@neurotec.ki.se